Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
P/E ratio for Longboard Pharmaceuticals, Inc. (LBPH)
P/E ratio as of 2023: -2.52
According to Longboard Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.52. At the end of 2022 the company had a P/E ratio of -1.30.
P/E ratio history for Longboard Pharmaceuticals, Inc. from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.52 |
| 2022 | -1.30 |
| 2021 | -3.00 |
| 2020 | -20.43 |